{"id":"NCT03117569","sponsor":"Kirby Institute","briefTitle":"Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients","officialTitle":"A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-21","primaryCompletion":"2018-12-19","completion":"2018-12-19","firstPosted":"2017-04-18","resultsPosted":"2019-12-11","lastUpdate":"2019-12-11"},"enrollment":380,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"glecaprevir (300mg)/pibrentasvir (120mg)","otherNames":["Mavyret"]}],"arms":[{"label":"Standard monitoring schedule","type":"OTHER"},{"label":"Simplified monitoring schedule","type":"EXPERIMENTAL"}],"summary":"The aim of this study is to determine if treatment monitoring schedule for chronic HCV patients treated with glecaprevir (300mg)/pibrentasvir (120mg) can be simplified.\n\nData has shown that direct acting antiviral (DAA) regimen of glecaprevir (300mg)/pibrentasvir (120mg), a protease inhibitor and NS5A inhibitor respectively , provides key features for HCV treatment simplification.\n\nEligible participants (naïve pre-cirrhosis chronic HCV patients) will be randomized (1:2) to the standard or simplified monitoring arm and will receive treatment for 8 weeks.\n\nOne post treatment visit will be conducted 12 weeks after the final dose of study medication to evaluate the proportion of patients with undetectable HCV RNA at this timepoint (SVR12).","primaryOutcome":{"measure":"Undetectable HCV RNA (ITT Population)","timeFrame":"12 weeks post end of treatment (SVR12)","effectByArm":[{"arm":"Standard Monitoring Schedule","deltaMin":121,"sd":null},{"arm":"Simplified Monitoring Schedule","deltaMin":233,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":33,"countries":["United States","Australia","Canada","France","Germany","New Zealand","Switzerland","United Kingdom"]},"refs":{"pmids":["31655134"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":127},"commonTop":["Fatigue","Headache","Nausea"]}}